A detailed introduction to Asciminib’s unique mechanism of action

Asciminib (Asciminib) is a new type of tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML). Compared with traditional TKI drugs such as imatinib and dasatinib, the biggest feature of aceminib is its unique target and mechanism of action. It is currently the first approved STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket), creating a new direction in CML treatment.

TraditionalTKIby blockingBCR-ABL1tyrosine kinase ATPbinding sites inhibit abnormal signaling, but as treatment time prolongs, mutations (such asT315I) often occur in patients, leading to resistance to traditional drugs. The uniqueness of acemini is that it does not act on the ATP binding site, but specifically targets the myelyl group of the ABL1 protein. The pocket site blocks the activation state of ABL1 through the "non-ATP site inhibition" mechanism, thereby effectively inhibiting signal transduction.

It is precisely because of this brand-new target that Asiminib can combat multiple TKI resistance mutations, especially the T315I mutation that is currently the most difficult to treat clinically. Clinical studies (such as the ASCEMBL trial) have shown that aceminib is effective in treating CMLTKI treatments. an> patients, it can still significantly increase the rate of major molecular response (MMR) and the incidence rate of deep molecular response (MR4.5), and the side effects are relatively mild, providing a new treatment option for refractory patients.

In addition, aceminib is highly selective in its action. It has a strong affinity for BCR-ABL1 but has less effect on other kinases, so it performs well in reducing "off-target effects". This high selectivity also makes patients better tolerated during long-term use, and the side effects are compared with traditional onesTKIFewer. To sum up, with its innovative STAMP mechanism, Asiminib not only expands the target range of TKI treatment, but also brings new hope for survival to patients with drug-resistant CML.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib